Innovation Pharmaceuticals Inc (IPIX)

[frrol]

The HDP-Ms developed by UoP are all based on arylamide backbones; they differ by the residues hanging off of it. Brilacidin showed the most promise, likely after screening assays. We relinquished our rights to other promising ones, to cut costs. UoP has the highly specialized research faculty and facilities for that development work, it's not something we could do even if we wanted to. Our limited capabilities are to license and clinically test them, and partner with pharmas to commercialize them. Completely different part of the development cycle.

Hopefully, with some capital in our pocket eventually, we can license some back.